Corcept Therapeutics shares surged after the FDA approved its drug, Lifyorli, for a tough ovarian cancer. This new therapy, combined with chemotherapy, showed a significant survival benefit in trials. The approval, coming early, offers hope for patients whose cancer no longer responds to standard treatments, though some patient groups are excluded.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets